Open AccessEtiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies
Author(s) -
Sanjoy Das,
Bhaskar Bhattacharya,
Biplajit Das,
Bibek Sinha,
Taison Jamatia,
Kishan Paul
Publication year - 2019
Publication title -
indian journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.231
H-Index - 16
eISSN - 0976-6952
pISSN - 0975-7651
DOI - 10.1007/s13193-019-00972-z
Subject(s) - cancer research , angiogenesis , medicine , tyrosine kinase , cancer , gefitinib , metastasis , crizotinib , oncogene , kinase , receptor tyrosine kinase , erlotinib , tumor progression , sorafenib , cancer cell , lung cancer , cell cycle , biology , epidermal growth factor receptor , microbiology and biotechnology , receptor , malignant pleural effusion , hepatocellular carcinoma
Cancer is one of the dominant causes of death worldwide while lifelong prognosis is still inauspicious. The maturation of the cancer is seen as a process of transformation of a healthy cell into a tumor-sensitive cell, which is held entirely at the cellular, molecular, and genetic levels of the organism. Tyrosine kinases can play a major, etiologic role in the inception of malignancy and devote to the uncontrolled proliferation of cancerous cells and the progression of a tumor as well as the development of metastatic disease. Angiogenesis and oncogene activation are the major event in cell proliferation. The growth of a tumor and metastasis are fully depending on angiogenesis and lymphangiogenesis triggered by chemical signals from tumor cells in a phase of rapid growth. Tyrosine kinase inhibitors are compounds that inhibit tyrosine kinases and effective in targeting angiogenesis and blocking the signaling pathways of oncogenes. Small molecule tyrosine kinase inhibitors like afatinib, erlotinib, crizotinib, gefitinib, and cetuximab are shown to a selective cut off tactic toward the constitutive activation of an oncogene in tumor cells, and thus contemplated as promising therapeutic approaches for the diagnosis of cancer and malignancies.